Rockville-based Supernus Pharmaceuticals, Inc. and Virginia-based Indivior Pharmaceuticals Announce Merger
In August, Rockville-based Supernus Pharmaceuticals, Inc. and Virginia-based Indivior Pharmaceuticals announced an all-stock merger that will combine the companies’ central nervous system (CNS) portfolios of medicines for neurological, psychiatrics, and addiction -related conditions, including treatments for opioid use disorder, attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The combined portfolios total approximately $2.2 billion in annual revenue, and the merger is expected to save both companies $125 million in annual costs.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases and was founded and established in 2005 through a spin-out of Shire, plc (now Takeda Pharmaceutical Company). The company then went public in 2012 and now employs over 500 people in Montgomery County. Following the completion of the merger with Indivior, Supernus’ headquarters in Rockville will serve as the company’s global headquarters.
The news of the merger follows recent announcements from Montgomery County’s biopharma ecosystem, which anchors the 3rd largest cluster in the nation:
The opening of Bora Pharmaceuticals’ new drug manufacturing facility in Rockville in July.
RegenXBio’s second IPO, at $90.4million, was the largest investment received by a local company in July. The Rockville-based clinical-stage biotechnology firm with 370 employees focuses on the development of gene therapy treatments for retinal, neuromuscular, and neurodegenerative diseases.
Germantown-based Precigen’s announcement on its first-ever quarterly profit, a year after its FDA approval for Papzimeos—an immunotherapy treatment for recurrent papillomatosis which affects nearly 27,000 people nationwide.
